Continue efforts through Eli Lilly & Company to develop oral tolerance therapy
Pilot studies of humans, while not establishing that oral tolerance therapy will be effective, have enabled some patients to stop taking conventional immunosuppressive drugs entirely.
In contrast, researchers theorize, oral tolerance therapy would cause T2 cells to release immunosuppressive cytokines only in areas that contain the target protein; in MS, for example, the target would be a specific brain protein.
Multiple sclerosis isn't alone in responding to oral tolerance therapy.
At the same time, the years of scientific studies that have preceded the clinical development of oral tolerance therapy
are clearly beginning to reverberate throughout the U.
Oral tolerance therapy
is a method for suppressing the immune system in the specific tissue where an autoimmune attack occurs.
This research creates a foundation to monitor the effects of oral tolerance therapy in patients undergoing treatment.
Weiner's research adds a key element to our understanding of oral tolerance therapy," said Robert C.
A placebo-controlled pilot trial of Myloral(TM) was conducted in 30 multiple sclerosis patients, to demonstrate the principle of oral tolerance therapy
in this disease.
There is a considerable body of scientific evidence showing that oral tolerance therapy is a promising approach to slowing and arresting the process of autoimmune disease.
The launch of these expanded trials is another important milestone towards our company's objective of bringing oral tolerance therapy to patients with immune disorders.
In oral tolerance therapy
, antigenic protein derived from the organ under attack -- in this case insulin from the pancreas -- is administered orally in precisely defined quantities.